Assessing the hemostatic effectiveness and safety of Surgicel® powder in complex cardiac surgeries: A retrospective case-series from a single surgeon at a tertiary hospital

Purpose: We conducted a retrospective case series to evaluate the application of Surgicel® Powder (oxidized regenerated cellulose) in cardiovascular procedures. Methods: We retrospectively reviewed medical records of patients who underwent complex cardiac surgeries between February 2022 and September 2023 at our institution. Patient demographics, operative procedures and post-operative follow up data were obtained. The primary efficacy end point was achieving hemostasis rate within 5 minutes of bleeding site application. Results: A total of 19 patients were enrolled; and all patients (100%) had comorbidities. The rate of major surgery (operative time ≥4 hours) was 100% (n=19 patients). 15 of 19 (84%) achieved hemostasis within 5 minutes, and the mean time to hemostasis was found to be 2.0 minutes. The total surgical procedure duration was 4 hrs (240 mins) and mean total postoperative hospital stay was 10.2 days (range 7-12). No safety signals were identified. Conclusion: Surgicel® Powder exhibited superior performance in achieving hemostasis in complex cardiac surgeries. No direct adverse effects associated with Surgicel® use were reported. Prospective comparative studies are needed in the future.